

Fresenius Kabi

Vermont New Product Launch Report

Last Updated - 3/30/2023

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
65219-0566-20	mitoMYcin Intravenous Solution Reconstituted 20 MG	3/7/2023

10 or 11 Digit NDC

This will include: Drug Trade Name,
Active Ingredient, Strength, and Size

Date Product was commercially
available

Key: **Used for Initial 3 Day Notice After Launch**

Used for Full Report Due 30 Days After Initial Notice

Submissions Made To AGO.highcostprescriptiondrugs@vermont.gov

WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
\$ 631.98	NONE	N
		Y/N
		Y/N
		Y/N

WAC on the date the Product was commercially available

A narrative description of the marketing and pricing plans used in the launch of the new prescription drug in the United States and internationally

Please respond with Yes or No

ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
100	N	N
	Y/N	Y/N
	Y/N	Y/N
	Y/N	Y/N

The estimated number of patients in the United States with a condition for which the new prescription drug may be prescribed

Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
		Y/N
		Y/N
		Y/N
		Y/N

If this field in N/A then please leave blank

If this field in N/A then please leave blank

Please respond with Yes or No

ACQUISITION PRICE COMMENT	GENERAL COMMENTS

If this field in N/A then please leave blank
